Chuan R. Jin

Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer.

Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer.

Journal: Journal for immunotherapy of cancer

Published: May 10, 2026

Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study.

Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study.

Journal: Signal transduction and targeted therapy

Published: June 20, 2025

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

Journal: Signal transduction and targeted therapy

Published: January 18, 2025

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study.

Journal: Cell reports. Medicine

Published: December 18, 2024

Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model.

Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model.

Journal: Molecular cancer therapeutics

Published: October 07, 2024

Biodistribution and toxicity evaluation of oncolytic adenovirus Adf35(OGN) in Syrian hamster and mouse.

Biodistribution and toxicity evaluation of oncolytic adenovirus Adf35(OGN) in Syrian hamster and mouse.

Journal: Cancer gene therapy

Published: September 29, 2024

Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas.

Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas.

Journal: Cancer immunology, immunotherapy : CII

Published: August 26, 2024

Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.

Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial.

Journal: Journal of hematology & oncology

Published: August 05, 2024

Targeting ZC3H11A elicits immunogenic cancer cell death through augmentation of antigen presentation and interferon response.

Targeting ZC3H11A elicits immunogenic cancer cell death through augmentation of antigen presentation and interferon response.

Journal: Molecular therapy. Nucleic acids

Published: March 26, 2024

Increased expression of LINC00323 correlates with tumor progression and poor prognosis of gastric cancer.

Increased expression of LINC00323 correlates with tumor progression and poor prognosis of gastric cancer.

Journal: Cancer biomarkers : section A of Disease markers

Published: August 07, 2023

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.

Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.

Journal: BMC cancer

Published: July 12, 2023

Effects of Different Primers on the Bond Strength to Properly and Excessively Etched Ceramic-coated Zirconia.

Effects of Different Primers on the Bond Strength to Properly and Excessively Etched Ceramic-coated Zirconia.

Journal: Operative dentistry

Published: February 18, 2023

Showing 1-12 of 59

Last Updated: 09/26/2026